LONDON, Jul 23, 2008 (Thomson Financial via COMTEX) - GSK | Quote | Chart | News | PowerRating -- Shares in GlaxoSmithKline Plc. were lower at midday after interim results failed to impress, with Hargreaves Lansdown saying the "results are likely to disappoint" investors.
At 1:29 a.m., GlaxoSmithKline shares were down 24-1/2 pence at 1,199-1/2, while the FTSE 100 index was ahead 60.9 points at 5,425.
ion. In conclusion, the results are likely to disappoint, with only the new management's strategy vision offering some consolation. On balance, market consensus opinion is neutral in tone."

LONDON (AFP) - British pharmaceutical giant GlaxoSmithKline said on Wednesday that net profits slipped during the second quarter owing to competition from generic drugmakers and poor sales of diabetes drug Avandia.
GSK's new chief executive Andrew Witty used his maiden results to unveil a major strategy overhaul aimed at diversifying the group's operations as it seeks higher growth and to reduce risk.
venues plunged by 46 percent to 194 million pounds in the reporting period.

LONDON - GlaxoSmithKline PLC, the world's second-largest drug maker, posted a three per cent drop in second-quarter profit on Wednesday, after strong competition from generic drugs outweighed asset sales and the cost-saving effects of job cuts.
As rising generic sales continue to eat away at its profits, Glaxo also unveiled plans to grab a share of that market itself, announcing an alliance with South African company Aspen Pharmacare Holdings.
ll year at constant exchange rates.

RESEARCH TRIANGLE PARK, NC - Internal drug development at pharmaceutical giant GlaxoSmithKline (NYSE: GSK) is about to get much more competitive in what’s being described as a “radical shakeup.”
Witty's interview came just before GSK announced a drop in profits today with the firm citing increasing competition from generics as a major reason.
e capitalist and a CEO of another biotech firm to help judge the development team’s efforts.

By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline, the world's second largest drugmaker, took a bold step into the branded generics marketplace on Wednesday via an alliance with South Africa's Aspen Pharmacare Holdings.
The move, paving the way for the sale of cheap medicines in emerging markets, is the latest sign of Glaxo diversifying the focus of its business in the face of tough conditions for patented drugs in the United States and Western Europe.
ing strong growth in volumes and branded generics in emerging markets do a lot better than they do in western markets," said Ben Yeoh, an analyst at Dresdner Kleinwort.

By Ben Hirschler LONDON, July 23 (Reuters) - GlaxoSmithKline Plc's new chief executive plans to make the world's second largest drugmaker a broader business

By Jonathan Russell The UK's largest pharmaceutical company GlaxoSmithKline has teamed up with South African generic drug company Aspen as part of its drive

By Trista Kelley July 23 (Bloomberg) - GlaxoSmithKline Plc, Europe's largest drugmaker, said second-quarter profit fell 3.5 percent after job cuts and asset sales failed to overcome a decline in revenue from the Avandia diabetes pill.
Net income dropped to 1.29 billion pounds ($2.58 billion), or 24.4 pence per share, from 1.33 billion pounds, or 23.7 pence, a year earlier, Glaxo said today in a statement. The London-based company was expected to earn 1.3 billion pounds, the median estimate of eight analysts surveyed by Bloomberg. Sales gained 3.5 percent to 5.87 billion pounds.
ere will be some next year, but now their position looks a bit better,'' Peter Cartwright, a

GlaxoSmithKline - has hit the US for its new general counsel, hiring Sidley Austin life sciences partner Dan Troy after a seven month search.
Former GSK general counsel Rupert Bondy joined energy company BP in May after announcing his departure in January this year. Troy will start the top job at GSK on 2 September.
fore joining Sidley Austin.

GlaxoSmithKline (GSK) on Wednesday announced a transformational agreement to significantly extend its pharmaceutical portfolio in emerging markets.

LONDON (Reuters) - GlaxoSmithKline (GSK.L: Quote, Profile, Research), the world's second largest drugmaker, took a bold step in the branded generics